LGC
and
Quotient Bioresearch
are pleased to announce that they have reached agreement on the sale by Quotient of its Bioanalytical Sciences division to LGC.
Quotient Bioanalytical Sciences is a leading provider of bioanalytical services across the fields of small molecules, biomarkers, biopharmaceuticals and microbiological testing to customers in the pharmaceutical and biotechnology sectors. It is based at Fordham, Cambridgeshire.
The acquisition, which will form part of LGC’s Health Sciences division, will enable LGC to provide an enhanced range of products and services to the pharmaceutical sector including bioanalysis, materials science and reference materials amongst others.
Under the terms of the transaction, Quotient and LGC have committed to collaborate as preferred partners on the provision of Bioanalytical Sciences. This will enable clients to continue to benefit from the early development services offered by the Quotient group including clinical trials, metabolism and radiolabelling. The Bioanalytical Sciences business will continue to trade using the “Quotient” name under its new ownership for the time being.
The transaction follows the sale two years ago by Quotient to LGC of HFL Sport Science, which is also based at the Fordham site.
Jeremy Cook, Managing Director of LGC’s Health Sciences said, “We’re delighted to have acquired Quotient Bioanalytical Sciences, a high quality business which is complementary to our existing activities. We continue to develop our range of first-rate services in the pharmaceutical, biotechnology and agrochemical sectors by offering our customers a unique mix of technical experience, leading edge facilities and knowledgeable people.”
Dr Steve Pleasance, Managing Director of Quotient Bioanalytical Sciences said “LGC’s focus on complex analytical chemistry, high quality science and service delivery make them a natural home for our business. Both our organisations have reputations built upon quality and innovation and LGC’s global presence will help support the continued growth of services to our customers.”
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.